insights_auto
Miks on MVIR tõusnud? 5,77%?
Uurige põhjalikumaltchevron_right
MVIR:STO
Medivir AB
1,69Â SEK
arrow_upward
+5,77%(+0,092) 1 p
2. okt, 17:29:51 GMT +2 · SEK
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse MVIR põhistatistika genereerimine…
Ava
1,71Â SEK
Kõrge
1,78Â SEK
Madal
1,67Â SEK
Turu kapit.
1,05Â mld
Keskm. maht
1,88Â mln
Maht
0,00
52 näd kõrgeim
2,88Â SEK
52 näd madalaim
0,34Â SEK
Aktsiatulu
−0,37 SEK
Käibivad aktsiad
624,18Â mln
Töötajate arv
6
Ava
1,71Â SEK
Kõrge
1,78Â SEK
Madal
1,67Â SEK
Turu kapit.
1,05Â mld
Keskm. maht
1,88Â mln
Maht
0,00
52 näd kõrgeim
2,88Â SEK
52 näd madalaim
0,34Â SEK
Aktsiatulu
−0,37 SEK
Käibivad aktsiad
624,18Â mln
Töötajate arv
6
Uudised
Veebiallikatest ja uudistepartneritelt
bloomingbit
·
1 tunni eest
UK’s OpenPayd Targets Nasdaq Listing This Year via Titan Acquisition Merger, Speeds US Expansion
Simply Wall Street
·
26 minuti eest
Is Delivery Update Altering The Investment Case For Li Auto (LI)?
Stock Traders Daily
·
4 tunni eest
(SLQD) Movement as an Input in Quant Signal Sets
Business Insider
·
18 tunni eest
The NYSE's Most Famous Floor Trader Says AI Can't Take His Job
Profiil
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Teave üksuse Medivir AB kohta